Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

  • Technology appraisal guidance
  • TA704
  • Published: 

Tools and resources

Tools and resources to help you put the guidance into practice.

Resource impact

Education

Guidance into practice